149281-19-6
|
|
|
- CAS号:
- 149281-19-6
- 英文名:
- CGP-53153
- 英文别名:
- CGP-53153;1H-Indeno[5,4-f]quinoline-7-carboxamide, N-(1-cyano-1-methylethyl)-2,4a,4b,5,6,6a,7,8,9,9a,9b,10,11,11a-tetradecahydro-4a,6a-dimethyl-2-oxo-, (4aR,4bS,6aS,7S,9aS,9bS,11aR)-
- 中文名:
- 149281-19-6
- 中文别名:
- 化合物 T10780
- CBNumber:
- CB23339639
- 分子式:
- C23H33N3O2
- 分子量:
- 383.52702
- MOL File:
- 149281-19-6.mol
|
|
|
149281-19-6化学性质
-
沸点:
-
627.0±55.0 °C(Predicted)
-
|
-
密度:
-
1.118±0.06 g/cm3(Predicted)
-
|
-
储存条件:
-
Store at -20°C
-
|
-
溶解度:
-
Soluble in DMSO
-
|
-
酸度系数(pKa):
-
12.88±0.60(Predicted)
-
|
149281-19-6性质、用途与生产工艺
CGP-53153是甾体类的 5 alpha reductase 抑制剂，在大鼠和人前列腺组织中的 IC50 值分别为36 nM。
IC50: 36 nM (rat 5 alpha reductase), 262 nM (human 5 alpha reductase)
CGP-53153 competitively inhibits rat microsomal 5 alpha reductase from prostate with an IC
50
of 36 nM compared to the reference compound finasteride (IC
50
=11 nM). CGP 53153 is approximately one order of magnitude more potent in inhibiting rat compared to human 5 alpha reductase, with IC
50
values of 36 and 262 nM, respectively
CGP-53153 can significantly reduce T-propionate-mediated prostate growth at oral doses of 0.01 mg/kg. CGP-53153 significantly reduces prostate weight at 3 and 10 mg/kg by 31% and 37%, respectively. Treatment for 12 weeks with both CGP-53153 reduces prostate volume by more than 70% in individual dogs. Neither body weight nor the weight of any organ tested is affected by CGP-53153.
149281-19-6
上下游产品信息
上游原料
下游产品
149281-19-6, 149281-19-6 相关搜索:
- 化合物 T10780
- 149281-19-6
- 1H-Indeno[5,4-f]quinoline-7-carboxamide, N-(1-cyano-1-methylethyl)-2,4a,4b,5,6,6a,7,8,9,9a,9b,10,11,11a-tetradecahydro-4a,6a-dimethyl-2-oxo-, (4aR,4bS,6aS,7S,9aS,9bS,11aR)-
- CGP-53153